Bio Impact Capital LLC Travere Therapeutics, Inc. Transaction History

Bio Impact Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $3.66 Million - $5.41 Million	239,204 Added 76.27%	552,846 $8.49 Million
Q1 2023 May 12, 2023	BUY	$17.82 - $22.89 $569,010 - $730,900	31,931 Added 11.33%	313,642 $7.05 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $96,985 - $137,261	5,251 Added 1.9%	281,711 $5.92 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $34,135 - $42,658	-1,490 Reduced 0.54%	276,460 $6.81 Million
Q1 2022 May 13, 2022	SELL	$23.61 - $30.6 $234,754 - $304,255	-9,943 Reduced 3.45%	277,950 $7.16 Million
Q4 2021 Feb 11, 2022	SELL	$24.34 - $31.17 $453,259 - $580,447	-18,622 Reduced 6.08%	287,893 $8.94 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $3.98 Million - $7.67 Million	306,515 New	306,515 $7.43 Million

199

85.2M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.35B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.